# Overcoming Endocrine Resistance in Metastatic Breast Cancer

> **NCT02394496** · PHASE3 · UNKNOWN · sponsor: **Consorzio Oncotech** · enrollment: 396 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Lapatinib
- **DRUG:** Aromatase Inhibitors
- **DRUG:** Placebo Lapatinib

## Key facts

- **NCT ID:** NCT02394496
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-11
- **Primary completion:** 2016-12
- **Final completion:** 2017-01
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2016-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02394496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02394496, "Overcoming Endocrine Resistance in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02394496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*